SIETES :: 92261 citas

Resultados de la búsqueda por TRATAMIENTO REFINAR BÚSQUEDA

1.

Benefits NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, Lawrence D, St Aubin L, Anthenelli RM. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers. A randomized clinical trial. JAMA Intern Med 2018:9 de abril. [Ref.ID 102506]

2.

The editors. FDA advisers recommend approval of non-opioid drug for opioid withdrawal. Physician's First Watch 2018:4. [Ref.ID 102485]

3.

Mitchell CM, Reed SD, Diem S, Larson JC, Newton KM, Ensrud KE, LaCroix AZ, Caan B, Guthrie KA. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms. A randomized clinical trial. JAMA Intern Med 2018:1. [Ref.ID 102472]

4.

Friedman BW, Irizarry E, Solorzano C, Latev A, Rosa K, Zias E, Vinson DR, Bijur PE, Gallagher EJ. Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine. Neurology 2017:18 de octubre. [Ref.ID 102194]

5.

Jull A, Wadham A, Bullen C, Parag V, Kerse N, Waters J. Low dose aspirin as adjuvant treatment for venous leg ulceration: pragmatic, randomised, double blind, placebo controlled trial (Aspirin4VLU). BMJ 2017;359:j5157. [Ref.ID 102158]

6.

Anónimo. Semma Therapeutics raises $114 million for new diabetes treatment. DIA Daily 2017:1. [Ref.ID 102151]

7.

Chang AK, Bijur PE, Esses D, Barnaby DP, Baer J. Effect of a single dose of oral opioid and nonopioid analgesics on acute extremity pain in the emergency department. A randomized clinical trial. JAMA 2017;318:1661-7. [Ref.ID 102137]

8.

Kyriacou DN. Opioid vs nonopioid acute pain management in the emergency department. JAMA 2017;318:1655-6. [Ref.ID 102136]

9.

Poewe W, Seppi K. Insulin signalling: new target for Parkinson's treatments?. Lancet 2017;390:1628-30. [Ref.ID 102093]

10.

Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Li Y, Avilés-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 2017;390:1664-16875. [Ref.ID 102092]

11.

Perreault S, de Denus S, White M, White-Guay B, Bouvier M, Dorais M, Dubé M-P, Rouleau J-L, Tardif J-C, Jenna S, Haibe-Kains B, Leduc R, Deblois D. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality. Pharmacoepidemiol Drug Saf 2017;26:81-90. [Ref.ID 101948]

12.

Bushnell G, Stürmer T, Gaynes BN, Pate V, Miller M. Simultaneous antidepressant and benzodiazepine new use and subsequent Long-term benzodiazepine use in adults with depression, United States, 2001-2014. JAMA Psychiatry 2017;74:747-55. [Ref.ID 101937]

13.

Guy Jr GP, Zhang K, Bohm MK, Lewis B, Young R, Murphy LB, Dowell D. Vital Signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66:697-704. [Ref.ID 101665]

14.

Mezzacappa A, Lasica P-A, Gianfagna F. Risk of autism spectrum disorders according to period of prenatal antidepressant exposure. A systematic review and meta-analysis. JAMA Pediatrics 2017;171:555-63. [Ref.ID 101641]

15.

Manhapra A, Rosenheck R. Opioid substitution treatment is linked to reduced risk of death in opioid use disorder. BMJ 2017;357:j1947. [Ref.ID 101635]

16.

Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017;357:j1550. [Ref.ID 101634]

17.

Anónimo. Actualización de insulinas. Infac: Información Farmacoterapéutica de la Comarca 2017;25:1-10. [Ref.ID 101631]

18.

Liu J, Li L, Deng K, Xu C, Busse JW, Vandvik PO, Li S, Guyatt GH, Sun X. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ 2017;357:j2499. [Ref.ID 101630]

19.

Patorno E, Huybrechts KF, Bateman BT, Cohen JM, Desai RJ, Mogun H, Cohen LS, Hernández-Díaz S. Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med 2017;376:2245-54. [Ref.ID 101629]

20.

Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 2017;376:2300-2. [Ref.ID 101628]